Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia

@inproceedings{Lutz2017ProgressiveML,
  title={Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia},
  author={Mathias Lutz and Arik Bernard Schulze and Elisabeth Rebber and Stefanie Wiebe and Tarek Zoubi and Oliver Martin Grauer and Torsten Kessler and Andrea Kerkhoff and Georg Lenz and Wolfgang E. Berdel},
  booktitle={Cancer research and treatment : official journal of Korean Cancer Association},
  year={2017}
}
Progressive multifocal leukoencephalopathy (PML) is a devastating neurological disease observed nearly exclusively in immunocompromised patients. Recently, the introduction of monoclonal antibodies significantly inhibiting the immune system such as rituximab has led to an increase in PML cases. Although rituximab-based immunochemotherapy remains the standard of treatment for chronic lymphocytic leukemia (CLL), the importance of Bruton's tyrosine kinase inhibitors such as ibrutinib is steadily… CONTINUE READING